- Hindocha, S., Campbell, D., Ahmed, M., Giorgakoudi, K., Sharma, B., Yousaf, N. … Lee, R.W. (2021). Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications. Frontiers in Medicine, 8. doi:10.3389/fmed.2021.764563.
- Ahmed, N., Giorgakoudi, K., Usuf, E., Okomo, U., Clarke, E., Kampmann, B. … Trotter, C. (2020). Potential cost-effectiveness of a maternal Group B streptococcal vaccine in The Gambia. Vaccine, 38(15), pp. 3096–3104. doi:10.1016/j.vaccine.2020.02.071.
- Giorgakoudi, K., O'Sullivan, C., Heath, P.T., Ladhani, S., Lamagni, T., Ramsay, M. … Trotter, C. (2018). Cost-effectiveness analysis of maternal immunisation against group B Streptococcus (GBS) disease: A modelling study. Vaccine, 36(46), pp. 7033–7042. doi:10.1016/j.vaccine.2018.09.058.
- Kohli-Lynch, M., Russell, N.J., Seale, A.C., Dangor, Z., Tann, C.J., Baker, C.J. … Lawn, J.E. (2017). Neurodevelopmental Impairment in Children After Group B Streptococcal Disease Worldwide: Systematic Review and Meta-analyses. Clinical Infectious Diseases, 65(suppl_2). doi:10.1093/cid/cix663.
- Giorgakoudi, K., Gubbins, S., Ward, J., Juleff, N., Zhang, Z. and Schley, D. (2015). Using Mathematical Modelling to Explore Hypotheses about the Role of Bovine Epithelium Structure in Foot-And-Mouth Disease Virus-Induced Cell Lysis. PLOS ONE, 10(10). doi:10.1371/journal.pone.0138571.
- Davies, H., O'Sullivan, C., Al Janabi, H., Rattue, H., Trotter, C., Giorgakoudi, K. … Heath, P. Neurodevelopmental outcomes following Group B Streptococcus Meningitis and Sepsis. Clinical Infectious Diseases.
Dr Kyriaki Giorgakoudi
Contact details
Address
Dr Kyriaki Giorgakoudi
M,
Myddelton Street Building
City, University of London
Northampton Square
London EC1V 0HB
United Kingdom
Northampton Square
London EC1V 0HB
United Kingdom
About
Overview
Dr Kyriaki Giorgakoudi joined City, University of London as Senior Research Fellow in Economic Evaluation in October 2019. She also holds an honorary contract with The Royal Marsden NHS Foundation Trust and is a Fellow of the Higher Education Academy.
Kyriaki has overlapping research interests in mathematical modelling, health economics, biomathematics, epidemiology, cancer and infectious diseases and has experience working in highly interdisciplinary environments.
Current Research Grants:
Co-Investigator & Health Economics Lead
NIHR, Efficacy and Mechanism Evaluation Programme, Precision Medicine. Title: Novel blood test to personalise Early Stage Colorectal Cancer treatment. Jan 2020 – Dec 2027, £2,953,289.
Co-Investigator
NIHR, Public Health Research, Title: The Kids Will Eat Better study: how can local authorities improve the efficiency and effectiveness of interventions to address inequality in childhood obesity?, September 2020-June 2023, £1,003,769
Co-Investigator & Health Economics Lead
NIHR, Programme Grant for Applied Research. Title: Integrating genetic testing into the prostate cancer pathway to more precisely guide care, treatment and accelerate clinical trials. Jan 2021 – Dec 2030, £3,001,779.
Qualifications
- PhD in Mathematical Modelling in Biology, Pirbright Institute & Loughborough University, United Kingdom
- MSc in Operational Research with Risk, University of Edinburgh, United Kingdom
- BSc in Mathematics, Aristotle’s University of Thessaloniki, Greece
- Postgraduate Certificate in Academic Practice (PgCAP), Brunel University London
Employment
- Senior Research Fellow, City, University of London, Oct 2019 – present
- Lecturer, Brunel University London, Sep 2018 – Sep 2019
- Research Fellow, City, University of London, Sep 2016 – Sep 2018
- Research Associate, University of Cambridge, Apr 2014 – Sep 2016
Publications
Publications by category
Conference paper/proceedings
- Anandappa, G., Starling, N., Peckitt, C., Bryant, A., Begum, R., Carter, P. … Cunningham, D. (2020). TRACC: Tracking mutations in cell-free DNA to predict relapse in early colorectal cancer-A randomized study of circulating tumour DNA (ctDNA) guided adjuvant chemotherapy versus standard of care chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer (CRC).